Semler Scientific, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
February 28, 2022 at 04:06 pm EST
Share
Semler Scientific, Inc. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was USD 53.03 million compared to USD 38.6 million a year ago. Net income was USD 17.22 million compared to USD 14.01 million a year ago.
Basic earnings per share from continuing operations was USD 2.56 compared to USD 2.13 a year ago. Diluted earnings per share from continuing operations was USD 2.12 compared to USD 1.74 a year ago.
Semler Scientific, Inc. provides technology solutions to healthcare providers. The Company develops, manufactures, and markets products and services that assist its customers in evaluating and treating chronic diseases. Its cardiac and vascular testing product, QuantaFlo, measures arterial blood flow in the extremities to aid in the diagnosis of peripheral arterial disease (PAD). QuantaFlo is a four-minute in-office blood flow test. Healthcare providers can use blood flow measurements as part of their examinations of a patient's vascular condition, including assessments of patients who have vascular disease. It has a distribution arrangement for the United States, including Puerto Rico, to distribute Insulin Insights, a software solution designed to provide insulin dosing recommendations to clinicians for the adjustment and maintenance of glucose levels in insulin-dependent patients with Type 2 diabetes. Its customers for QuantaFlo include insurance plans, physician groups, and others.